Skip to main content
Knowledge-Pathway-Hero-image

Potential to Improve Patient Care Through Identifying Inefficiencies

The Leica Biosystems Process and Solutions Optimization team partnered with a private teaching hospital. Hospital Administration was interested in several areas pertaining to the breast care program including:

Initial Data

  • Recommendations and current evidence to inform and encourage improved surgical timeliness to care and adjuvant therapy after initial biopsy
  • Recommendations relative to process and efficiency improvements for breast needle localizations followed by surgeries
  • Recommendations for reduction in outmigration

The Leica Biosystems team conducted a three-day on site visit to the breast center and found several opportunities for improvement.

Image
Potential to Improve Patient Care Through Identifying Inefficiencies

Recommendations

Potential to improve efficiencies from biopsy to surgery

Use of needle localizations was a cumbersome process and was identified to cause delay in surgery. Earlier start times for needle localizations were instituted. The team should explore, pilot, and record any efficiencies from the move of the use of needle localizations to the magnetic seed to see if there is improvement in surgical timeliness.

Potential to improve efficiencies from surgery to adjuvant therapy

Oncotype Dx testing: The test is intended for use in all newly diagnosed patients with early-stage (stage I, II or IIIa), breast cancer who have node-negative or node-positive (1-3), estrogen receptor-positive (ER+),  HER2 -negative disease, and with DCIS for determination of appropriate therapy. The test can be run on a post-lumpectomy tumor sample or on a core biopsy. Oncotype Dx should be ordered by the breast surgeon, so it does not delay further treatment. Turnaround time for the test is approximately two weeks.

Program Promotion

The Leica Biosystems team recommends this facility should display banners or information regarding the CoC accreditation, NAPBC accreditation and Center of Excellence awards.

Projected Outcomes*

Projected Outcomes include:

  • Decrease in the number of days from biopsy to initial surgery – currently at 31 days.
  • Decrease in the number of days from biopsy to adjuvant therapy – currently at 68–77 days.
  • Reduction of the outmigration percentage – currently at 19.3%.

Projections and Realized Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.


El contenido de Leica Biosystems Knowledge Pathway está sujeto a las condiciones de uso del sitio web de Leica Biosystems, disponibles en: Aviso legal.. El contenido, incluidos los webinars o seminarios web, los recursos de formación y los materiales relacionados, está destinado a proporcionar información general sobre temas concretos de interés para los profesionales de la salud y no está destinado a ser, ni debe interpretarse como asesoramiento médico, normativo o jurídico. Los puntos de vista y opiniones expresados en cualquier contenido de terceros reflejan los puntos de vista y opiniones personales de los ponentes/autores y no representan ni reflejan necesariamente los puntos de vista ni opiniones de Leica Biosystems, sus empleados o sus agentes. Cualquier enlace incluido en el contenido que proporcione acceso a recursos o contenido de terceros se proporciona únicamente por comodidad.

Para el uso de cualquier producto, debe consultarse la documentación correspondiente del producto, incluidas las guías de información, los prospectos y los manuales de funcionamiento.

Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.